United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 12

Name: Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 12 comparison snapshot
Creator: Fliar BI Prism

A five-company biological products, excluding disgnostic substances cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderCandel Therapeutics · 47

Strongest available pathCandel Therapeutics · +71.0%

Widest latest marginOrganovo · -1727.8%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1CADL · Nasdaq

Candel Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1999Needham, Massachusetts$1.00B market cap

View full Companies Radar profile

47Cautious

Snapshot price$13.07as of page date

Monthly-close return+71.0%five-year window

FY2023 revenue$0.00BCandel Therapeutics, Inc.

Net margin-30351.2%FY2023

P/E snapshot-20.9xone ratio, not a verdict

Prism attention14.3%share across these five

Filing track recordRevenue, USD billions

+0.0%

FY2021–FY2023 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 0.0%

52-week position90% through range

$4.35$14.00

News mentions520

Community mentions7partial coverage

U.S.-scope patents27

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal55/100
Management stability90/100
Market position0/100
Capital-event signal69/100
Innovation pulse7/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 3 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2VIVS · Nasdaq

Organovo

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2007San Diego$3.8M market cap

View full Companies Radar profile

41Cautious

Snapshot price$0.29as of page date

Monthly-close return-99.7%five-year window

FY2025 revenue$0.00BVivoSim Labs, INC.

Net margin-1727.8%FY2025

Prism attention34.2%share across these five

Filing track recordRevenue, USD billions

-93.4%

FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -49.4%

52-week position1% through range

$0.26$5.30

News mentions1.2K

Community mentions0partial coverage

U.S.-scope patents273

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal32/100
Management stability90/100
Market position17/100
Capital-event signal65/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 9 M&A involvements, 3 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3CVM · NYSE

Cel-Sci

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1983Vienna, Virginia$27.4M market cap

View full Companies Radar profile

40Cautious

Snapshot price$1.56as of page date

Monthly-close return-99.5%five-year window

FY2014 revenue$0.00BCEL SCI CORP

Net margin-10364.7%FY2014

P/E snapshot-0.2xone ratio, not a verdict

Prism attention24.3%share across these five

Filing track recordRevenue, USD billions

+3.7%

FY2012–FY2014 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1.8%

52-week position6% through range

$0.89$12.68

News mentions881

Community mentions45partial coverage

U.S.-scope patents71

Prism InsightsWhat sits behind the readiness signal
Observed risk 10/100higher means more observed risk

Earnings signal39/100
Management stability90/100
Market position5/100
Capital-event signal81/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 4 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4SNTI · NASDAQ

Senti Biosciences

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2016San Francisco, California$11.7M market cap

View full Companies Radar profile

37Cautious

Snapshot price$0.38as of page date

Monthly-close return-99.6%five-year window

FY2025 revenue$0.00BSenti Biosciences, Inc.

Net margin-279263.6%FY2025

P/E snapshot-0.4xone ratio, not a verdict

Prism attention9.7%share across these five

Filing track recordRevenue, USD billions

-99.3%

FY2022–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -91.8%

52-week position2% through range

$0.33$2.88

News mentions351

Community mentions3partial coverage

U.S.-scope patents270

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal44/100
Management stability90/100
Market position7/100
Capital-event signal32/100
Innovation pulse3/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5ATYR · Nasdaq

aTyr Pharma

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2005San Diego, California$53.0M market cap

View full Companies Radar profile

37Cautious

Snapshot price$0.54as of page date

Monthly-close return-89.9%five-year window

FY2025 revenue$0.00BaTYR PHARMA INC

Net margin-39009.5%FY2025

P/E snapshot-1.2xone ratio, not a verdict

Prism attention17.5%share across these five

Filing track recordRevenue, USD billions

-98.2%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -63.3%

52-week position2% through range

$0.40$6.50

News mentions634

Community mentions30partial coverage

U.S.-scope patents534

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal33/100
Management stability90/100
Market position0/100
Capital-event signal51/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Candel Therapeutics

+71.0%

aTyr Pharma

-89.9%

Cel-Sci

-99.5%

Senti Biosciences

-99.6%

Organovo

-99.7%

Latest revenue

USD billions, official filing scope shown on each company card.

Candel Therapeutics

$0.00B

Organovo

$0.00B

Cel-Sci

$0.00B

Senti Biosciences

$0.00B

aTyr Pharma

$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Organovo

-1727.8%

Cel-Sci

-10364.7%

Candel Therapeutics

-30351.2%

aTyr Pharma

-39009.5%

Senti Biosciences

-279263.6%

Prism news attention

Normalized share across these five names; attention is not quality.

Organovo

34.2%

Cel-Sci

24.3%

aTyr Pharma

17.5%

Candel Therapeutics

14.3%

Senti Biosciences

9.7%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Organovo leads the conversation

It holds 34.2% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $0.00B.

Price path

Candel Therapeutics leads the available price paths

Its monthly-close return is +71.0% for the five-year window. At the other end, Organovo is -99.7% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Organovo has the widest latest margin

Its FY2025 net margin is -1727.8%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Candel Therapeutics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -20.9x while its five-year window price return is +71.0%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · VIVS

Organovo

1,241available Prism news records

Prism top themes

Leadership & governance

Price action & investor response

Capital allocation & transactions

Macro demand & rates

Earnings & financial performance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-22.2%77 latest 12m vs 99 prior 12m

Machine-classified coverage tone

95.9% positive+3.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

3d printer software 21additive manufacturing system 17wearable biotech 11biomaterials 113d printed drugs 83d printed implants 8anti-tnf therapy crohn's 7biologic agents crohn's 7

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-02–2026-06-01 · trend and themes shown through 2026-06

Areas of research · CVM

Cel-Sci

881available Prism news records

Prism top themes

Legal, arbitration & regulatory

Price action & investor response

Capital allocation & transactions

Earnings & financial performance

Macro demand & rates

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-79.0%52 latest 12m vs 248 prior 12m

Machine-classified coverage tone

93.8% positive-3.3 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

initial public offering 15stock price 14stock performance 14public offering 13stock surge 11relapsed hodgkin's immunotherapy 9share price 9vaccine formulation 8

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-15–2026-06-01 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

CVM

Cel-Sci

45 mentions

Stock and valuation

Products, pricing and logistics

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 45 records remained after filtering.

ATYR

aTyr Pharma

30 mentions

Stock and valuation

Products, pricing and logistics

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 30 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

CADL

Candel Therapeutics

through 2026-05-01

Listing / IPO 5Company announcements 3Earnings releases 2

2026-05-01
Company announcements
Today announced that on April 30, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to two new employees, stock options to purchase an aggregate of 29,400 shares of the Company’s common stock, with a per share exercise price of $6.18.
2026-02-20
Listing / IPO
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the pricing of an underwritten public offering of 18,348,624 shares of its common stock at a price to the public of $5.45 per share.
2024-11-19
Earnings releases
The company reported a net loss of $10.6 million, attributing this mainly to changes in warrant liabilities.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

VIVS

Organovo

through 2025-04-03

Leadership changes 4Asset acquisitions 3Company announcements 1Earnings releases 1Lawsuits 1

2025-04-03
Earnings releases
Organovo’s preliminary cash and cash equivalents balance was approximately $11.3 million as of the end of the fiscal year on March 31, 2025.
2025-03-26
Asset acquisitions
Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced the successful close of the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company (NYSE:LLY) (“Lilly”). The transaction was completed on March 25, 2025.
2025-03-20
Company announcements
Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced that it will effect a 1-for-12 reverse stock split of its issued and outstanding common stock that will become effective at 5:00 p.m. Eastern Time on Thursday, March 20, 2025.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CVM

Cel-Sci

through 2025-09-01

Listing / IPO 8Earnings releases 4Leadership changes 4Regulatory 4M&A 2

2025-09-01
Regulatory
It has applied for Breakthrough Medicine Designation for Multikine, an immunotherapy for head and neck cancer, with the Saudi Food & Drug Authority.
2025-08-28
Listing / IPO
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 1,111,200 shares of its common stock.
2025-02-14
Leadership changes
Cel-Sci Corp. named F. Donald Hudson and Edwin A. Shallowayto its board.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SNTI

Senti Biosciences

through 2025-12-18

Company announcements 6Leadership changes 5Business contracts 3Earnings releases 3M&A 2

2025-12-18
Company announcements
Senti Bio’s Board of Directors granted to one new employee stock options to purchase an aggregate of 13,680 shares of the Company’s common stock with a per share exercise price of $1.31 per share.
2025-05-12
Lawsuits
Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. ("Senti" or the "Company").
2025-03-14
Leadership changes
Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio,” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Feng Hsiung, an executive with extensive business, finance and investment experience, to the Senti Bio Board of Directors (the “Board”).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ATYR

aTyr Pharma

through 2025-09-08

Earnings releases 9Company announcements 7Leadership changes 4

2025-09-08
Company announcements
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted three employees nonstatutory stock options to purchase an aggregate of 62,400 shares of aTyr’s common stock, each with an exercise price of $5.71 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on September 3, 2025, the effective date of the grants.
2025-05-07
Earnings releases
Atyr Pharma Inc. (ATYR) on Wednesday reported a loss of $14.9 million in its first quarter.
2025-03-27
Leadership changes
aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”) today announced the appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence

2020 extracted base$194.20B–$477.15B

2033 extracted forecast$685.30B–$1.37T

Implied source CAGR8.5%

high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

24,998available Prism news records

Latest 12m volume+9.8%10786 vs 9825 records

Positive classified tone41.7%+4.6 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies

4,078

substance abuse education

3,736

opioid addiction and treatment

3,643

overdose prevention techniques

3,482

controlled substance regulations

3,381

substance abuse overdose fatalities

3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

mind-altering drug consumption 1,795opioid diversion abuse 1,702fentanyl treatment programs 1,649drug overdose 1,576cannabis policy reform discussions 1,328psychedelic mental health studies 1,328medication-assisted treatment opioids 1,265psychoactive drug intake 1,170

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

harm reduction strategies

4,078 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

2,049 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

Biosimilars entering the market

1,542 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+9.8% news volume

The latest 12 months contain 10,786 matched records versus 9,825 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

41.7% positive · +4.6pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 56–62. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Candel Therapeutics leads the readiness ranking

Its Prism readiness score is 47/100, the highest in this five-company comparison.

Open Candel Therapeutics in Companies Radar

Scale and margin leadership sit with Cel-Sci and Organovo

Cel-Sci has the largest displayed latest revenue at $0.00B; Organovo has the widest displayed latest margin at -1727.8%.

Open Cel-Sci in Companies Radar Open Organovo in Companies Radar

Comparisons

Strongest versus weakest available price path

Candel Therapeutics is +71.0% for its five-year window; Organovo is -99.7% for its five-year window.

Open Candel Therapeutics in Companies Radar Open Organovo in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.00B for Cel-Sci to $0.00B for Cel-Sci. Entity and filing-period labels remain visible on the company cards.

Open Cel-Sci in Companies Radar

Anomalies

Candel Therapeutics has the widest attention-readiness rank gap

It ranks #4 by measured news attention (14.3%) and #1 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Candel Therapeutics in Companies Radar

Cel-Sci shows a price-operating divergence to inspect

Its displayed filing-revenue change is +3.7% while its available monthly-close return is -99.5%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Cel-Sci in Companies Radar

Explanations

Attention measures coverage volume, not quality

Organovo's 34.2% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Organovo in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Candel Therapeutics's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 47/100 score.

Open Candel Therapeutics in Companies Radar

Stress-test the largest divergence before forming a view

Compare Cel-Sci's profile with Candel Therapeutics's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Cel-Sci in Companies Radar Open Candel Therapeutics in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.